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Abstract
Electroconvulsive therapy (ECT) was first experienced in 1938 and had been conducting without anesthesia for 30 years. In this
study, the most common indication for ECT was mood disorder (major depressive disorder and bipolar I disorder). We introduce a
patient with a history of COVID-19 and suicide who required emergency ECT. Electroconvulsive therapy can be life-saving in patients
with suicide history or catatonic schizophrenia. Health workers are at the front line of the COVID-19 outbreak control and must
follow health instructions. Aerosol-producing procedures such as suction in anesthesia for ECT may facilitate the transmission of
infectious diseases such as COVID-19. When performing aerosol-producing procedures during the pandemic of novel coronavirus,
every patient should be considered suspicious.
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1. Introduction
The novel coronavirus can cause acute respiratory dis-
ease that was first identified in December 2019 in Wuhan.
It has affected more than five million people worldwide
(1, 2). Some COVID-19 patients have psychological diseases
that require medical treatment or electroconvulsive ther-
apy under general anesthesia. Electroconvulsive therapy
(ECT) can be life-saving in patients with suicide history or
catatonic schizophrenia.
Health workers are at the front line of the COVID-
19 outbreak control and must follow health instructions.
Aerosol-producing procedures such as suction in anesthe-
sia for ECT may facilitate the transmission of infectious dis-
eases such as COVID-19. Due to the high risk of these proce-
dures, in terms of virus infection, the procedures should
be performed with complete protective equipment.
2. Case Presentation
On March 30, a 25-year-old male patient, weighing
85 kg, without any past medical history, was admitted
to the hospital with fever, cough, headache, and muscle
pain symptoms. Chest CT scan revealing of pulmonary in-
volvement led to a COVID-19 diagnosis, as shown in Fig-
ure 1. Thus, the patient was prescribed acetaminophen
naproxen and hydroxychloroquine. The patient had the
experience of irritable mood, increased self-esteem, re-
duced need for sleep, talkativeness, agitation, and psy-
chotic symptoms like grandiosity delusion, auditory, and
visual hallucination. Finally, he drank a small amount of
bleach solution to disinfect his body. Then, he was trans-
ferred to the hospital by the emergency medical service.
According to an interview with the patient and his fam-
ily, the patient was diagnosed with bipolar I disorder and
manic episodes with psychotic symptoms.
The patient had BP 100/60 mmHg, PR125, and SPO2 86%
at the time of hospitalization. He had no fever but com-
plained of mild coughs and dyspnea. He was prescribed
coltra, azithromycin, and sodium valproate. During the
hospitalization, to control the aggressive behaviors of the
patient, 20 mg of haloperidol (IM), 10 mg of biperiden (IM),
and 100 mg of chlorpromazine (IM) were administered
daily. The patient was hospitalized for one week in the
emergency department and then at the general ward. He
was visited by an emergency medical service and ENT spe-
cialist, and the required radiographies were taken, which
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showed no damage to the airway due to the bleach. Due to
the little volume of the fluid and normal results of CT scan
and endoscopy, no treating action for the digestive system
was conducted. Because of the poor patient’s response to
treatment, ECT was conducted in six steps on 4th, 8th, 10th,
12th, 14th, and 16th April.
Figure 1. Lung CT scan of the patient
Based on the procedure, ECT should be conducted in
the Department of Psychiatry of a hospital; however, re-
garding the likelihood of the transmission of COVID-19 to
other ECT patients, the therapy was conducted in a section
devoted to patients with acute respiratory syndrome us-
ing proper personal protective equipment (PPE). Full PPE
was provided for all medical personnel, including gloves,
aprons, long-sleeved gowns, N95 masks, eye goggles, face
visors, and shoe covers. For anesthesia, a circulation sys-
tem with a manual ventilator was used. The patient was
fully monitored while using a peripheral venous catheter.
The patient received 20 mg succinylcholine chloride and
200 mg sodium thiopental. After the induction of anesthe-
sia, a dental guard was inserted to protect the teeth, and
then, electroshocks of 35, 50, 65, 80, and 100 volts were
induced, in sequence, in the six steps. The ECT resulted
in generalized seizures for 25 to 35 seconds. During the
anesthesia and recovery, the patient received 500 cc of nor-
mal saline infusion serum. Masking, manual ventilation,
and suction were all carried out under an appropriate plas-
tic cover to avoid the spreading of the novel coronavirus.
Relaxants and anesthetics were such dosed to minimize
the requirement for manual ventilation. After 30 minutes
of recovery at the end of each ECT step, the patient was
transferred to the ward. After the simultaneous comple-
tion of COVID-19 treatment and improving the mood and
psychotic symptoms, the patient was discharged from the
hospital with good general conditions. The treatment was
followed by oral haloperidol, oral sodium valproate, and
oral bipyridine.
3. Discussion
Electroconvulsive therapy (ECT) was first experienced
in 1938 and had been conducting without anesthesia for
30 years (3). The most common indication for ECT is mood
disorder (major depressive disorder and bipolar I disor-
der). It should be considered for use in patients who do not
tolerate medications, have severe or psychotic symptoms,
are acutely suicidal or homicidal, or have marked symp-
toms of agitation or stupor (4). Electroconvulsive therapy
is usually conducted three times per week and can be con-
tinued for two to four weeks. Patients usually show signs
of improvement after receiving ECT three to five times
(5). Using ECT with scalp electrodes results in a spike-and-
wave pattern of the electroencephalogram (EEG) in the pa-
tient, which is accompanied by generalized seizure and
cardiovascular stimulation, followed by increased cerebral
blood flow (CBF) and intracranial pressure (ICP) (6). Hemo-
dynamic responses to ECT can even cause myocardial is-
chemia (7). The seizures of EEG that last for 25 to 50 seconds
can result in the optimal treatment (8). Most of the anes-
thetics have anti-seizure effects and can reduce the time of
seizures based on the dosage. The overuse of anesthetics
can weaken the response to ECT by reducing the time of
seizure.
Methohexital is considered the gold standard for ECT
(9). Other anesthetics used for these patients are sodium
thiopental and etomidate. The latter can cause longer
seizures in patients with short seizures (10). Thiopental is
preferred over propofol for ECT anesthesia induction (11).
Not taking a muscle relaxant before ECT may lead to more
severe myalgia. Using relaxants is a common practice to
reduce myalgia and prevent bone fracture and joint dislo-
cation. To this end, succinylcholine is the most frequently
used relaxant (12). Since ECT is conducted three to four
times per week and takes a few minutes, tracheal intuba-
tion is not a common practice, except for patients in their
late pregnancy or on a full stomach (13). Circulation or sim-
ple bag-mask is usually used for ventilation. In obese pa-
tients with obstructive sleep apnea, an airway can be used.
Most COVID-19 patients exhibit neurological manifes-
tations. In a study, notably, 26 out of 40 patients (65%) hos-
pitalized in the ICU showed agitation, and 69% of relax-
ant takers showed agitation after medication discontinu-
ation (14). The novel coronavirus can be found in the brain
or cerebrospinal fluid of patients. Even though the respi-
ratory system is the most involved part in COVID-19, pa-
tients can show some neurological demonstrations such
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as paresthesia headache, mood disorder, and attention
deficit (15). During the COVID-19 pandemic, some of the pa-
tients that go to the hospital for other reasons may be in-
fected with the novel coronavirus. Also, some of the COVID-
19 patients may require treatment under general anesthe-
sia.
Electroconvulsive therapy can be life-saving in patients
with suicide history or catatonic schizophrenia. Thus,
ECT cannot always be postponed during the COVID-19 pan-
demic regarding that it is an elective service. Using proper
PPE is mandatory during ECT for susceptible novel coro-
navirus patients, as the patients can spread the virus af-
ter ventilation by masks or manual bags via cough or dis-
charges. Personnel should be equipped with two-layer
gloves, long-sleeved gowns, and proper masks, and Ambu
bags should be connected to antiviral filters if possible. It is
suggested that the patients be effectively preoxygenated to
decrease their requirement for ventilation by the manual
bag. Also, a disposable bite block should be used. The dis-
tance between patients during recovery should be at least
six feet. The number of the medical crew should be kept
minimum, and, if possible, the procedure should be con-
ducted in a negative pressure room (16, 17).
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